Vad vill ett företag som Elekta få ut av svensk ... - NovaMedTech
Vad vill ett företag som Elekta få ut av svensk ... - NovaMedTech
Vad vill ett företag som Elekta få ut av svensk ... - NovaMedTech
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
<strong>Elekta</strong><br />
Research and global business<br />
development<br />
Sören Johansson,<br />
Vice President, Business development
Hjärt-lungmaskiner<br />
Ett historiskt perspektiv<br />
- från Innovation till Industri<br />
Strålkniven<br />
Radioterapi<br />
Dialys<strong>ut</strong>rustningen<br />
Titanimplantat<br />
Hörselimplantat<br />
AGA<br />
Mikromekanisk trycksensor<br />
<strong>Elekta</strong><br />
Gambro<br />
Ett resultat <strong>av</strong> <strong>ett</strong> nära<br />
samarbete mellan industri,<br />
akademi och sjukvården<br />
Nobel Biocare<br />
Entific / Cochlear<br />
Radi Medical / St Jude
Ett historiskt perspektiv<br />
- från Innovation till Industri<br />
Pacemakern<br />
Operation och sårbehandling<br />
Infektionskontroll, kirurgi<br />
och intensivvård<br />
Implantat, urologi, kirurgi och<br />
andningshjälpmedel<br />
Digital röntgen<br />
Siemens Elema / St Jude<br />
IT lösningar i sjukvården<br />
Mölnlycke Health Care<br />
Getinge<br />
Astra Tech<br />
Sectra<br />
Cambio
<strong>Elekta</strong> – one of the fastest growing companies<br />
in radiation therapy<br />
* Incl. acquisition of Nucletron<br />
• Every year over 1,000,000 patients<br />
benefit from treatment with radiation<br />
therapy equipment from <strong>Elekta</strong><br />
• One of the fastest growing<br />
companies in the radiation therapy<br />
field<br />
• Close to 3,400 employees<br />
worldwide*<br />
• Net sales SEK 9.0 bn,<br />
operating result SEK 1.8 bn, margin<br />
20%<br />
• Headquarters in Stockholm, Sweden<br />
offices in abo<strong>ut</strong> 40 countries
Strong growth with increased profitability<br />
Net Sales EBIT<br />
SEK M SEK M
Million<br />
25<br />
20<br />
15<br />
10<br />
5<br />
0<br />
Cancer incidence is growing<br />
12,7<br />
Cancer incidence<br />
13,3<br />
15,0<br />
16,9<br />
19,1<br />
21,4<br />
2008 2010 2015E 2020E 2025E 2030E<br />
Lung<br />
Breast<br />
Colorectum<br />
Stomach<br />
Prostate<br />
Liver<br />
Cervix <strong>ut</strong>eri<br />
Oesophagus<br />
Bladder<br />
Non-Hodgkin …<br />
Leukaemia<br />
Most frequent cancers<br />
0,4<br />
0,4<br />
0,4<br />
0,5<br />
0,5<br />
0,7<br />
0,9<br />
1,0<br />
1,2<br />
1,4<br />
1,6<br />
0,0 0,5 1,0 1,5<br />
Number of new cancer cases per year (millions, 2008)<br />
Source: Globocan 2008<br />
2010A 2030E<br />
World population:<br />
7.0 bn<br />
Population +60 years, world:<br />
760 M<br />
Age group +60 years will<br />
grow at the highest pace<br />
+20%<br />
+82%<br />
8.3 bn<br />
1.4 bn<br />
Approx. 60 percent* of all new cancer<br />
cases occur in age group +60 years
Från innovation till generisk <strong>ut</strong>veckling<br />
Gamma Knife ®<br />
surgery<br />
Stereotactic<br />
Radiation Therapy<br />
Medicinteknik är “applied science”; nya upptäckter inte<br />
nödvädigt för att <strong>ut</strong>veckla nya och viktiga lösningar –<br />
“Generisk FoU”<br />
Volumetric Modulated<br />
Arc therapy<br />
Image Guided<br />
Radiation Therapy<br />
Precision Radiation<br />
Therapy
Measurements<br />
”The old days”<br />
• ”Simple” sol<strong>ut</strong>ions<br />
• Direct to end-user<br />
• Not so expensive to<br />
commercialise<br />
Analysis<br />
”From treatment and system to<br />
disease management”<br />
Information<br />
Knowledge<br />
”Today & tomorrow”<br />
• Complex sol<strong>ut</strong>ions<br />
• Clinical sol<strong>ut</strong>ions<br />
• Organisational impact<br />
• Internationalization<br />
• High commercialisation costs<br />
Wisdom
Technology as a facilitator for a changing<br />
practice….<br />
1950-2000 2000-2011<br />
Todays objectives<br />
„<br />
Avoid adjacent<br />
critical structures<br />
„<br />
Maximize dose<br />
to tumor<br />
„<br />
High quality,<br />
efficient delivery<br />
1. Sol<strong>ut</strong>ions for effective radiotherapy<br />
2. Workflow<br />
3. Efficiency<br />
4. Simplicity
Evol<strong>ut</strong>ion of <strong>Elekta</strong>’s role in cancer care<br />
Technology<br />
• IMRT<br />
• IGRT<br />
Sol<strong>ut</strong>ions<br />
• Agility TM<br />
• VMAT<br />
• MOSAIQ ® RTP<br />
• Flexitron sol<strong>ut</strong>ion<br />
Disease pathways<br />
• <strong>Elekta</strong> Lung<br />
Research Group<br />
• <strong>Elekta</strong> Clarity ®<br />
consortium<br />
• <strong>Elekta</strong> Spine<br />
consortium<br />
• Leksell Gamma<br />
Knife ® Society<br />
Comprehensive<br />
sol<strong>ut</strong>ions<br />
• Disease<br />
management<br />
• Full offering<br />
• Data management<br />
- informatics<br />
• More service and<br />
upgrades
Emerging markets<br />
Leadership and strong growth<br />
2004/05<br />
20%<br />
• Invest ahead of the curve<br />
• Focus on training and education<br />
• Product development specialized<br />
for emerging markets<br />
*Net sales, rounded figures<br />
80%<br />
2011/12<br />
30%<br />
70%<br />
Emerging markets Mature markets<br />
2014/15E<br />
40%<br />
60%
<strong>Elekta</strong> has strong performance<br />
in emerging markets<br />
<strong>Elekta</strong> emerging markets<br />
Net sales, SEK bn<br />
1,3<br />
CAGR<br />
26% *<br />
1,9<br />
2,2<br />
*Excl. Nucletron CAGR is 22%<br />
2,6<br />
08/09 09/10 10/11 11/12<br />
No.1<br />
(shared)<br />
No. 1<br />
No. 1<br />
No. 1
Innovation through collaboration
Collaboration with leading clinical centers<br />
Centers of Excellence<br />
SPI/Swedish Hospital, Seattle<br />
IGRT/VMAT Clinical Program<br />
Princess Margaret Hospital, Toronto<br />
IGRT Clinical Program<br />
KS, Stockholm<br />
SRS<br />
UPMC, Pittsburgh<br />
SRS<br />
William Beumont Hospital, Detroit<br />
NKI-AVL, Amsterdam<br />
IGRT/4D Clinical Program<br />
UMC, Utrecht<br />
IGRT Clinical Program<br />
Mannheim University Clinic<br />
IMRT / VMAT Clinical Program<br />
EMR / MOP Clinical Program<br />
Key<br />
R&D and Clinical Training<br />
Clinical Residency Training (Eur)<br />
Wurzburg University Clinic<br />
SRT Clinical Program<br />
• Partners in R&D<br />
• Workflow<br />
• Clinical publications<br />
• Financial feasibility<br />
• Risk assessment<br />
BNI – Beijing<br />
• Regulatory demand<br />
Western China Univ – Huaxi<br />
Tokyo University Hospital
Sverige <strong>som</strong> bas för en medicinteknisk<br />
<strong>företag</strong>s<strong>ut</strong>veckling<br />
1. Det <strong>svensk</strong>a sjukvårdssystemet har en bra vision, det krävs dock en<br />
kontinuerlig klinisk <strong>ut</strong>veckling inom sjukvården för att bibehålla ledarskap<br />
2. Det finns <strong>ett</strong> behov att balansera pragmatisk leverans <strong>av</strong> vård med<br />
forskning och klinisk <strong>ut</strong>veckling för att <strong>ut</strong>veckla patientvården<br />
3. Vår sjukvårdsfinansiering har skapat felaktiga drivkrafter på <strong>av</strong>delningsnivå<br />
- budgetsystem kontrollerar kostnader <strong>ut</strong>an att belöna förbättrad ”o<strong>ut</strong>come”<br />
4. Svaghet i besl<strong>ut</strong>sfattande och auktoritet vid implementering <strong>av</strong> förändringar<br />
inom sjukvårdsorganisationen<br />
5. Sjukvården i Sverige saknar insikten att industrin är en viktig partner till<br />
dem i arbetet att <strong>ut</strong>veckla densamma<br />
6. Industrin är ej en passiv intressent.
För<strong>ut</strong>sättningar för samverkan industrisjukvård<br />
• Attityd<br />
– Transparens samt öppenhet att<br />
se industrin <strong>som</strong> en partner i<br />
arbetet att <strong>ut</strong>veckla sjukvården<br />
– Skapa en gemensam vision <strong>av</strong><br />
<strong>ett</strong> partnerskap där industrin<br />
samt sjukvården samarbetar för<br />
att <strong>ut</strong>veckla en kostnadseffektiv<br />
sjukvård
För<strong>ut</strong>sättningar för samverkan industrisjukvård<br />
• Budget och organisation<br />
– Sjukvården bör skapa ekonomiskt<br />
samt organisatoriskt <strong>ut</strong>rymme <strong>som</strong><br />
möjliggör samverkan med industrin<br />
samt tydliga ledningsformer och<br />
spelregler<br />
– Förändrad syn på hur<br />
upphandlingsregler tillämpas i<br />
samverkansprojekt och<br />
innovationsupphandling
<strong>Elekta</strong> R&D in Sweden<br />
- conditions for collaboration with academia in Sweden<br />
• Strong internal R&D in Sweden<br />
– 150% organic growth since the year 2000<br />
– Now around 80 engineers in Stockholm, working in<br />
close collaboration with other <strong>Elekta</strong> R&D centers<br />
globally<br />
– Recent addition of 35 engineers in Uppsala (Nucletron<br />
acquisition)<br />
• Swedish R&D is internationally competitive<br />
– Excellent supply of competence<br />
– Example: Recent recruitment of one Research Engineer to <strong>Elekta</strong><br />
Stockholm resulted in 100+ qualified applicants, o<strong>ut</strong> of which more<br />
than 40 had Ph.D. degrees<br />
– Several Swedish universities h<strong>av</strong>e started Master programs in<br />
Medical Engineering<br />
– Creativity and problem-solving mindset<br />
– Straight communication and transparency<br />
– Reasonable cost structure
<strong>Elekta</strong> Research & Development Sites<br />
St Louis<br />
Sunnyvale<br />
(Information systems)<br />
(US imaging)<br />
(Treatment planning)<br />
June 2012<br />
Montreal<br />
Stockholm<br />
(Neuro)<br />
Crawley<br />
(Oncology)<br />
Atlanta<br />
(Treatment planning)<br />
Uppsala<br />
(Brachy, RTP)<br />
Milano<br />
(Oncology)<br />
Helsinki<br />
(Neuro)<br />
Veenendaal<br />
(Brachy)<br />
Schwabmünchen<br />
(Oncology)<br />
Beijing<br />
(Oncology)<br />
Shanghai<br />
(RTP/Neuro)<br />
Product development<br />
driven by customer needs,<br />
in close collaboration with<br />
leading centers worldwide
Research collaboration with hospitals<br />
Industry perspective<br />
<strong>Elekta</strong> has many active clinical and technical collaborations with<br />
hospitals and universities around the world, b<strong>ut</strong> most large projects<br />
are o<strong>ut</strong>side Sweden<br />
• Access to clinical expertise is a key success<br />
factor for developing innovative products<br />
• From the industry perspective, an ideal partner<br />
has:<br />
– Established scientific leadership in the relevant<br />
area<br />
– Access to additional funding (hospital, regional,<br />
national, international)<br />
– A shared vision and passion to create innovative<br />
and cost efficient healthcare sol<strong>ut</strong>ions<br />
• Geographical proximity helps b<strong>ut</strong> is not a<br />
requirement
Ongoing research collaborations in Sweden<br />
Swedish partners Project<br />
Linköping University, Lund University,<br />
Linköping University Hospital<br />
• Fluorescence spectroscopy for neurosurgery<br />
Karolinska Hospital • Narrow beam dosimetry and Monte Carlo simulations<br />
Chalmers University of Technology<br />
(VINN Excellence Centre Chase)<br />
Chalmers University of Technology<br />
(EU project with 13 partners)<br />
Uppsala University Hospital<br />
CTMH, Stockholm<br />
CMIV, Linköping<br />
• Leksell Gamma Knife treatment planning (M.Sc. project)<br />
• Stereotactic radiotherapy<br />
• Hyperthermia for head and neck cancer<br />
• Hybrid MEG-MRI Imaging System<br />
• Radiotherapy planning<br />
• ”Clinical Innovation Fellowship”, Team Onkologi<br />
• industridoktorandbidrag ?? VR, ”Avancerade MR-metoder för<br />
funktionell och stereotaktisk neurokirurgi”
1. Ny<strong>företag</strong>ande vs <strong>ut</strong>veckling <strong>av</strong> etablerat <strong>företag</strong><br />
2. Nya innovationer vs Vidare<strong>ut</strong>veckling <strong>av</strong> befintliga produkter<br />
3. Akademisamarbeten vs Kliniksamarbeten<br />
4. Akademi och Industri har samma behov och mål<br />
– Ledarskap<br />
– Excellence<br />
– Competence<br />
– Behov <strong>av</strong> samverkan (Industri – akademi)<br />
– Tillgång till sjukvård och klinik
Change language